PubMed:33089863 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":87,"end":92},"obj":"Body_part"},{"id":"T2","span":{"begin":430,"end":435},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma7199"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7199"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":38,"end":46},"obj":"Disease"},{"id":"T2","span":{"begin":47,"end":56},"obj":"Disease"},{"id":"T3","span":{"begin":74,"end":101},"obj":"Disease"},{"id":"T4","span":{"begin":207,"end":231},"obj":"Disease"},{"id":"T5","span":{"begin":233,"end":241},"obj":"Disease"},{"id":"T6","span":{"begin":359,"end":367},"obj":"Disease"},{"id":"T7","span":{"begin":417,"end":443},"obj":"Disease"},{"id":"T8","span":{"begin":445,"end":448},"obj":"Disease"},{"id":"T10","span":{"begin":524,"end":527},"obj":"Disease"},{"id":"T12","span":{"begin":627,"end":635},"obj":"Disease"},{"id":"T13","span":{"begin":693,"end":740},"obj":"Disease"},{"id":"T14","span":{"begin":693,"end":726},"obj":"Disease"},{"id":"T15","span":{"begin":838,"end":846},"obj":"Disease"},{"id":"T16","span":{"begin":894,"end":897},"obj":"Disease"},{"id":"T18","span":{"begin":928,"end":936},"obj":"Disease"},{"id":"T19","span":{"begin":991,"end":994},"obj":"Disease"},{"id":"T21","span":{"begin":1021,"end":1029},"obj":"Disease"},{"id":"T22","span":{"begin":1043,"end":1051},"obj":"Disease"},{"id":"T23","span":{"begin":1304,"end":1312},"obj":"Disease"},{"id":"T24","span":{"begin":1385,"end":1392},"obj":"Disease"},{"id":"T25","span":{"begin":1430,"end":1438},"obj":"Disease"},{"id":"T26","span":{"begin":1583,"end":1590},"obj":"Disease"},{"id":"T27","span":{"begin":1655,"end":1663},"obj":"Disease"},{"id":"T28","span":{"begin":1664,"end":1673},"obj":"Disease"},{"id":"T29","span":{"begin":1771,"end":1779},"obj":"Disease"},{"id":"T30","span":{"begin":1829,"end":1832},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005052"},{"id":"A9","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005052"},{"id":"A11","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005052"},{"id":"A17","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005052"},{"id":"A20","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A23","pred":"mondo_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A24","pred":"mondo_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/MONDO_0011122"},{"id":"A25","pred":"mondo_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A26","pred":"mondo_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/MONDO_0011122"},{"id":"A27","pred":"mondo_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A28","pred":"mondo_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A29","pred":"mondo_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A30","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005052"},{"id":"A31","pred":"mondo_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":243,"end":246},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T2","span":{"begin":371,"end":372},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":483,"end":485},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T4","span":{"begin":647,"end":648},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":684,"end":688},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T6","span":{"begin":877,"end":878},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T7","span":{"begin":1413,"end":1414},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T8","span":{"begin":1783,"end":1784},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":324,"end":339},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_50846"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":74,"end":101},"obj":"Phenotype"},{"id":"T2","span":{"begin":417,"end":443},"obj":"Phenotype"},{"id":"T3","span":{"begin":445,"end":448},"obj":"Phenotype"},{"id":"T4","span":{"begin":524,"end":527},"obj":"Phenotype"},{"id":"T5","span":{"begin":894,"end":897},"obj":"Phenotype"},{"id":"T6","span":{"begin":991,"end":994},"obj":"Phenotype"},{"id":"T7","span":{"begin":1385,"end":1392},"obj":"Phenotype"},{"id":"T8","span":{"begin":1583,"end":1590},"obj":"Phenotype"},{"id":"T9","span":{"begin":1829,"end":1832},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A4","pred":"hp_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A6","pred":"hp_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A7","pred":"hp_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/HP_0001513"},{"id":"A8","pred":"hp_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/HP_0001513"},{"id":"A9","pred":"hp_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/HP_0002037"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"LitCovid-PubTator","denotations":[{"id":"4","span":{"begin":38,"end":46},"obj":"Disease"},{"id":"5","span":{"begin":47,"end":56},"obj":"Disease"},{"id":"6","span":{"begin":60,"end":68},"obj":"Species"},{"id":"7","span":{"begin":74,"end":101},"obj":"Disease"},{"id":"37","span":{"begin":201,"end":226},"obj":"Disease"},{"id":"38","span":{"begin":233,"end":241},"obj":"Disease"},{"id":"39","span":{"begin":359,"end":367},"obj":"Disease"},{"id":"40","span":{"begin":403,"end":411},"obj":"Species"},{"id":"41","span":{"begin":417,"end":443},"obj":"Disease"},{"id":"42","span":{"begin":445,"end":448},"obj":"Disease"},{"id":"43","span":{"begin":474,"end":482},"obj":"Species"},{"id":"44","span":{"begin":524,"end":527},"obj":"Disease"},{"id":"45","span":{"begin":627,"end":635},"obj":"Disease"},{"id":"46","span":{"begin":693,"end":740},"obj":"Species"},{"id":"47","span":{"begin":838,"end":846},"obj":"Disease"},{"id":"48","span":{"begin":894,"end":897},"obj":"Disease"},{"id":"49","span":{"begin":898,"end":906},"obj":"Species"},{"id":"50","span":{"begin":928,"end":936},"obj":"Disease"},{"id":"51","span":{"begin":991,"end":994},"obj":"Disease"},{"id":"52","span":{"begin":995,"end":1003},"obj":"Species"},{"id":"53","span":{"begin":1021,"end":1029},"obj":"Disease"},{"id":"54","span":{"begin":1043,"end":1051},"obj":"Disease"},{"id":"55","span":{"begin":1072,"end":1080},"obj":"Species"},{"id":"56","span":{"begin":1304,"end":1312},"obj":"Disease"},{"id":"57","span":{"begin":1385,"end":1392},"obj":"Disease"},{"id":"58","span":{"begin":1430,"end":1438},"obj":"Disease"},{"id":"59","span":{"begin":1562,"end":1567},"obj":"Disease"},{"id":"60","span":{"begin":1583,"end":1590},"obj":"Disease"},{"id":"61","span":{"begin":1655,"end":1663},"obj":"Disease"},{"id":"62","span":{"begin":1664,"end":1673},"obj":"Disease"},{"id":"63","span":{"begin":1771,"end":1779},"obj":"Disease"},{"id":"64","span":{"begin":1815,"end":1823},"obj":"Species"},{"id":"65","span":{"begin":1829,"end":1832},"obj":"Disease"}],"attributes":[{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"MESH:C000657245"},{"id":"A5","pred":"tao:has_database_id","subj":"5","obj":"MESH:D007239"},{"id":"A6","pred":"tao:has_database_id","subj":"6","obj":"Tax:9606"},{"id":"A7","pred":"tao:has_database_id","subj":"7","obj":"MESH:D015212"},{"id":"A37","pred":"tao:has_database_id","subj":"37","obj":"MESH:C000657245"},{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"MESH:C000657245"},{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"MESH:C000657245"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"MESH:D015212"},{"id":"A42","pred":"tao:has_database_id","subj":"42","obj":"MESH:D015212"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"Tax:9606"},{"id":"A44","pred":"tao:has_database_id","subj":"44","obj":"MESH:D015212"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:C000657245"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"Tax:2697049"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:C000657245"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D015212"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"Tax:9606"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:C000657245"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D015212"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Tax:9606"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:C000657245"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:C000657245"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"Tax:9606"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:C000657245"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D009765"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:C000657245"},{"id":"A59","pred":"tao:has_database_id","subj":"59","obj":"MESH:D003643"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"MESH:D009765"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:C000657245"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D007239"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:C000657245"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"Tax:9606"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:D015212"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":102},"obj":"Sentence"},{"id":"T2","span":{"begin":103,"end":114},"obj":"Sentence"},{"id":"T3","span":{"begin":115,"end":268},"obj":"Sentence"},{"id":"T4","span":{"begin":269,"end":450},"obj":"Sentence"},{"id":"T5","span":{"begin":451,"end":459},"obj":"Sentence"},{"id":"T6","span":{"begin":460,"end":587},"obj":"Sentence"},{"id":"T7","span":{"begin":588,"end":741},"obj":"Sentence"},{"id":"T8","span":{"begin":742,"end":864},"obj":"Sentence"},{"id":"T9","span":{"begin":865,"end":873},"obj":"Sentence"},{"id":"T10","span":{"begin":874,"end":937},"obj":"Sentence"},{"id":"T11","span":{"begin":938,"end":1030},"obj":"Sentence"},{"id":"T12","span":{"begin":1031,"end":1170},"obj":"Sentence"},{"id":"T13","span":{"begin":1171,"end":1368},"obj":"Sentence"},{"id":"T14","span":{"begin":1369,"end":1495},"obj":"Sentence"},{"id":"T15","span":{"begin":1496,"end":1568},"obj":"Sentence"},{"id":"T16","span":{"begin":1569,"end":1674},"obj":"Sentence"},{"id":"T17","span":{"begin":1675,"end":1687},"obj":"Sentence"},{"id":"T18","span":{"begin":1688,"end":1833},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":102},"obj":"Sentence"},{"id":"T2","span":{"begin":103,"end":114},"obj":"Sentence"},{"id":"T3","span":{"begin":115,"end":268},"obj":"Sentence"},{"id":"T4","span":{"begin":269,"end":450},"obj":"Sentence"},{"id":"T5","span":{"begin":451,"end":459},"obj":"Sentence"},{"id":"T6","span":{"begin":460,"end":587},"obj":"Sentence"},{"id":"T7","span":{"begin":588,"end":741},"obj":"Sentence"},{"id":"T8","span":{"begin":742,"end":864},"obj":"Sentence"},{"id":"T9","span":{"begin":865,"end":873},"obj":"Sentence"},{"id":"T10","span":{"begin":874,"end":937},"obj":"Sentence"},{"id":"T11","span":{"begin":938,"end":1030},"obj":"Sentence"},{"id":"T12","span":{"begin":1031,"end":1170},"obj":"Sentence"},{"id":"T13","span":{"begin":1171,"end":1368},"obj":"Sentence"},{"id":"T14","span":{"begin":1369,"end":1495},"obj":"Sentence"},{"id":"T15","span":{"begin":1496,"end":1568},"obj":"Sentence"},{"id":"T16","span":{"begin":1569,"end":1674},"obj":"Sentence"},{"id":"T17","span":{"begin":1675,"end":1687},"obj":"Sentence"},{"id":"T18","span":{"begin":1688,"end":1833},"obj":"Sentence"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":102},"obj":"Sentence"},{"id":"T2","span":{"begin":103,"end":114},"obj":"Sentence"},{"id":"T3","span":{"begin":115,"end":268},"obj":"Sentence"},{"id":"T4","span":{"begin":269,"end":450},"obj":"Sentence"},{"id":"T5","span":{"begin":451,"end":459},"obj":"Sentence"},{"id":"T6","span":{"begin":460,"end":587},"obj":"Sentence"},{"id":"T7","span":{"begin":588,"end":741},"obj":"Sentence"},{"id":"T8","span":{"begin":742,"end":864},"obj":"Sentence"},{"id":"T9","span":{"begin":865,"end":873},"obj":"Sentence"},{"id":"T10","span":{"begin":874,"end":937},"obj":"Sentence"},{"id":"T11","span":{"begin":938,"end":1030},"obj":"Sentence"},{"id":"T12","span":{"begin":1031,"end":1170},"obj":"Sentence"},{"id":"T13","span":{"begin":1171,"end":1368},"obj":"Sentence"},{"id":"T14","span":{"begin":1369,"end":1495},"obj":"Sentence"},{"id":"T15","span":{"begin":1496,"end":1568},"obj":"Sentence"},{"id":"T16","span":{"begin":1569,"end":1674},"obj":"Sentence"},{"id":"T17","span":{"begin":1675,"end":1687},"obj":"Sentence"},{"id":"T18","span":{"begin":1688,"end":1833},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases.\nBACKGROUND: The effect of immunosuppressive treatment for immune-mediated diseases on risk of the novel coronavirus disease 2019 (COVID-19) has not been established. We aimed to define the effect of targeted biologic and immunomodulator therapy on risk of COVID-19 in a multi-institutional cohort of patients with inflammatory bowel disease (IBD).\nMETHODS: We identified patients 18 years and older who received care for IBD at Partners Healthcare between January 2019 and April 2020. The primary outcome was development of COVID-19 defined as a positive polymerase chain reaction test for severe acute respiratory syndrome coronavirus 2. Multivariable regression models were used to examine the effect of immunosuppression on risk of COVID-19 and its outcomes.\nRESULTS: In a cohort of 5302 IBD patients, 39 (0.7%) developed COVID-19. There was no difference in age, sex, or race between IBD patients with and without COVID-19. The rate of COVID-19 was similar between patients treated with immunosuppression (0.8%) compared with those who were not (0.64%; P = 0.55). After adjusting for age, sex, race, and comorbidities, use of immunosuppressive therapy was not associated with an increased risk of COVID-19 (odds ratio, 1.73; 95% confidence interval, 0.82-3.63). The presence of obesity was associated with a higher risk of COVID-19 (odds ratio, 8.29; 95% confidence interval, 3.72-18.47). There were 7 hospitalizations, 3 intensive care unit stays, and 1 death. Older age and obesity but not immunosuppressive treatment were associated with severe COVID-19 infection.\nCONCLUSIONS: The use of systemic immunosuppression was not associated with an increased risk of COVID-19 in a multi-institutional cohort of patients with IBD."}